Develops B‑cell–focused, rapid antibody‑eliciting preventive vaccines based on a patented single‑component self‑assembling protein nanoparticle (1c‑SApNP) platform. Applies the platform to address major global pathogens including HIV, RSV/hMPV, PIV1–5, filoviruses, coronaviruses, HCV, ZIKV/DENV, malaria and tuberculosis.